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Lifetime attributable secondary cancer risk
A B S T R A C T
Immune checkpoint inhibitors (ICI) have improved outcomes for patients with advanced cancers, and results in
increasing numbers of long-term survivors. For registration studies, progression-free survival and disease-free
survival often serve as primary endpoints. This requires repeated computed tomography (CT) scans for tumour
imaging which might lead to major radiation exposure. To determine this, all immune checkpoint inhibitors
trials that led to FDA approval were retrieved up to July 29, 2019. From the available protocols, imaging
modalities and schedules used in each trial were identified. The anticipated cumulative number of scans made
after 1, 3, 5, and 10 years study participation were calculated. The percentage of lifetime attributable cancer risk
was calculated using the Biological Effects of Ionizing Radiation VII report. Fifty-one trials were identified, from
which 39 protocols were retrieved. Four were adjuvant trials. All protocols required repeated chest-abdomen
imaging and specified CT scans as preferred imaging modality. Median calculated cumulative numbers of chest-
abdomen CT scans after 1, 3, 5, and 10 years study participation were 7, 16, 24 and 46, respectively. For ages
20–70 years at study entry, the average lifetime attributable cancer risk after 1 year of study participation ranged
from 1.11 to 0.40% for men and from 1.87 to 0.46% for women. At 10 years study participation, this risk
increased to a range of 5.91 to 1.96% for men and 9.64 to 2.32% for women. Given high imaging radiation
exposure for long-term survivors in current ICI trials an adaptive imaging interval and imaging termination rules
should be considered for long-term survivors.
Introduction
Immune checkpoint inhibitors (ICI) have improved the outcomes for
patients with advanced cancers, also resulting in increased numbers of
long-term survivors in subgroups of patients with metastatic disease or
irresectable tumors. In advanced stage melanoma, for example, a
pooled analysis has shown an overall survival (OS) rate of 20% at
10 years in patients treated with ipilimumab. An OS rate of 34% at
5 years was seen when given a programmed cell death protein 1 (PD-1)
antibody, for treatment-naïve patients this was 40% [1–3]. Increased
numbers of long-term survivors in a subgroup were also observed in
other diseases, including a 5-year OS rate of 28% in heavily pre-treated
patients with renal cell cancer and a 16% OS rate with non-small-cell
lung carcinoma [4]. Moreover, ICI has increased long-term OS in the
adjuvant setting in patients with melanoma [5].
For registration studies, progression-free survival (PFS) and disease-
free survival (DFS) often serve as primary endpoints. This requires re-
peated computed tomography (CT) scans for tumor imaging. Given the
expanding group of patients experiencing long-term survival from ICI,
trial participation could therefore lead to major radiation exposure.
This ionizing radiation can induce DNA damage and increases the risk
of second cancer development [6].
The aim of this study was to analyze protocols of ICI trials to de-
termine expected imaging radiation exposure. Information regarding
radiation exposure during screening, treatment and follow-up was ex-
tracted and used to estimate the lifetime attributable risk (LAR) of ra-
diation-induced cancer.
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Trial and protocol identification
All ICI trials that led to Food and Drug Administration (FDA) ap-
proval were identified up to July 29, 2019. Protocols were collected
from the journals in which trial results were published as well as from
ClinicalTrials.gov.
Imaging data acquisition
The imaging modalities that were allowed in the protocols were
identified and the corresponding radiation exposure for trial partici-
pants was calculated for 1, 3, 5 and 10 years of study participation. The
protocols were checked for specification of an adaptive imaging in-
terval for long-term survivors that extended the imaging interval to>
3 months. We also reviewed whether the protocols specified imaging
termination criteria for long-term survivors and a risk/benefit assess-
ment for exposure to ionizing radiation from imaging.
Calculation of the imaging-induced lifetime attributable cancer risk
We calculated the LAR of imaging-radiation-induced cancer by
using the risk estimates published in the Biological Effects of Ionizing
Radiation (BEIR) VII report [7], which estimated the LAR of cancer
resulting from a single 0.1 Gy dose based on sex, age and exposed or-
gans. We interpolated the age of exposure to the nearest year of age. For
our calculations, a dose of 16.5 mSv was used for a chest-abdomen CT
scan (in oncology this includes the pelvis). This was the mean effective
radiation dose of a chest-abdomen CT scan reported in a recent analysis
of standardized data from over 2 million CT scans in adults obtained at
institutions in Europe, the U.S.A., Israel and Japan [8].
Results
Trial and protocols
The search yielded 51 trials, four of which were in the adjuvant
setting and the others in the metastatic setting. For 12 trials the pro-
tocols were not publicly available and were excluded, 39 trials were
analyzed. All included trials were of recent date (2011–2019).
Imaging modalities and protocols
All protocols included mandatory repeated imaging of the chest and
abdomen. Although 33 protocols specified MRI as an alternative, 19 of
them stated that CT scans were preferred or that MRI scans were al-
lowed only if CT scans were contraindicated. Another five protocols
stated that MRI scans were allowed for abdomen but not for chest
imaging. If imaging of the brain was requested, MRI was preferred.
Therefore, brain imaging rarely contributed to radiation exposure.
Other less common imaging modalities are summarized in
Supplementary Appendix Table 1 with data retrieved for these mod-
alities and the imaging protocols used.
Eight trials, three in the adjuvant setting, had an adaptive increasing
imaging interval with longer follow up. Four trials, including one ad-
juvant trial, had criteria for imaging termination. Only the adjuvant
CheckMate 238 trial had both and therefore requested the fewest scans.
All 39 trials required that the same assessment method and the same
technique be used during the trial and follow-up. Only the adjuvant
CheckMate 238 trial, provided an imaging-induced ionizing radiation
risk/benefit assessment.
Fig. 1 shows the estimated number of protocol-requested chest-ab-
domen scans made after 1, 3, 5 and 10 years of study participation in
the ICI trials. The median cumulative number of chest-abdomen CT
scans per patient after each of these four time points were 7, 16, 24 and
46. In the four adjuvant trials, the total number of such scans per pa-
tient ranged between 5–7, 11–16, 15–24 and 15–46, respectively.
Calculation of LAR of radiation-induced cancer
The LAR of secondary cancer depends on the cumulative radiation
dose, which increases with longer trial participation. Furthermore, it
depends on the patient’s age at the start of study participation and on
the patient’s sex. After 1 year of trial participation, the average LAR was
1.11% for a 20-year-old male and 1.87% for a 20-year-old female. With
higher age at start of study participation, the average LAR was lower.
For example, the average LAR was 0.40% for 70-year-old males and
0.46% for 70-year-old females. After 10 years of study participation the
LAR increased to 5.91–1.96% for men and 9.64–2.32% for women (for
ages between 20 and 70 at study entry). Figs. 2 and 3 show the esti-
mated LAR of cancer for patients in ICI trials with different ages at the
start of study participation.
Discussion
This study shows that ICI trials for FDA registration used imaging
protocols that resulted in high cumulative radiation exposure for pa-
tients. This exposure can induce secondary cancers in long-term survi-
vors, with the highest risk in young women.
The risk of carcinogenesis due to ionizing radiation from CT scan-
ning in patients with solid tumors has become increasingly apparent
[6], especially after patients with metastasized testicular cancer
achieved complete remissions and cures. Consequently, it became ob-
vious that imaging procedures had to be reduced to avoid secondary
cancer [9,10]. Before the ICI era, patients with advanced solid cancer
apart from testicular cancer patients, had a very high chance of re-
currence or progressive disease and did not live long enough to develop
imaging induced secondary cancer. However, ICI improved the out-
comes for a subgroup of patients with advanced solid cancers, resulting
in increased number of long-term survivors, some of them may even be
cured [1–3]. As shown in our analysis, these long-term survivors have a
high risk to develop secondary cancer due to imaging radiation. Al-
though regular response measurements of patients in ICI trials is of
importance to avoid continuation of an inactive treatment and to
Fig. 1. Estimated number of protocol-requested chest-abdomen scans (CT or
MRI) in the immune checkpoint inhibitor trials. Data from 39 trials, of which
four were adjuvant trials. The box-and-whisker plot represents the estimated
number of scans after 1, 3, 5 and 10 years study participation in immune
checkpoint inhibitor trials. The boxes represent the median cumulative number
of chest-abdomen CT scans per patient after each of these four time points: 7,
16, 24 and 46 (horizontal bar) and quartile one and three (lower and upper
ends of boxes). The whiskers extend to the highest (9, 21, 33, 66) and lowest (5,
11, 14 and 14) numbers of scans for each time point.
D.G. Knapen, et al. Cancer Treatment Reviews 87 (2020) 102027
2
determine PFS or DFS, we now have to consider the radiation burden as
well. This requires that we have to balance the pros and cons of fre-
quent imaging in long-term survivors in ICI trials.
Our results show that a similar approach as for testicular cancer
patients should be considered regarding imaging procedures during and
after ICI treatment. Investigators can use the ICRP publication 62 for
assessing if the use of radiation is justified [11]. It adheres to the as low
as reasonably achievable (ALARA) principle of radiation safety
designed to minimize radiation doses and release of radioactive mate-
rials. To justify radiation, the risk / benefit ratio should be described.
The cumulative imaging radiation dose can be reduced by opti-
mizing CT protocols. Currently, the CT scan radiation dose varies
greatly between countries and institutions. For example, the mean ef-
fective dose of a chest-abdomen CT scan in Germany is 10.0 mSv, while
this is 37.9 mSv in Japan [8]. This variation is attributable to scan
parameter settings and reconstruction algorithms and not to patient
characteristics or the machine manufacturer or model [8]. Protocol
sharing across institutions could help optimize and standardize CT ef-
fective doses [8]. Moreover, an adapted imaging interval, meaning
longer imaging intervals with longer follow up, which was used in three
of the four of adjuvant ICI studies we analyzed (Figs. 1 and 3), could
reduce radiation burden. In future trials, CT scans could also be re-
placed, where possible, by other modalities such as MRI scans [12].
Improved accessibility and advanced technology have accelerated the
use of MRI and its acceptance in clinical practice [11]. Furthermore,
software that automates imaging radiation dose tracking in electronic
patient files could give treating physicians real-time insight into the
total radiation exposure of their patients [13].
Our analysis has a few limitations. First, the calculations were done
by using the risk estimates of the BEIR VII report which uses the linear
no-threshold (LNT) model [7]. The LNT model provides a risk estimate
based on the assumption that long-term, biological damage caused by
ionizing radiation is directly proportional to the radiation dose. Any
exposure to ionizing radiation, however small, can induce cancer. The
sum of several very small exposures is considered to have the same
effect as one larger exposure (response linearity). The general validity
of the LNT hypothesis for extrapolations from effects of high to repeated
low doses has been questioned [14,15]. However, evidence is provided
for the existence of nonlinear biological responses in the low and
medium dose range as well as effects other than the classical DNA da-
mage [16]. In a retrospective cohort study a positive association be-
tween radiation dose from CT scans and leukaemia (excess relative risk
per mGy 0.036, 95% CI 0.005–0.120; p = 0.0097) and brain tumours
(0.023, 0.010–0.049; p = 0.0001) was seen [17]. The model is also
recommended by advisory bodies such as the International Commission
on Radiological Protection (ICRP) [18]. Therefore, we think this model
Fig. 2. Average lifetime attributable risk (LAR) of imaging-radiation-induced
cancer incidence. The stacked bar chart represents the estimated average LAR
of cancer due to protocol-requested chest-abdomen CT scans in all immune
checkpoint inhibitor trials analyzed: 39 trials of which 4 were adjuvant trials.
The analysis was based on an estimated effective dose 16.5 mSv. The data are
presented separately for males (blue) and females (red).
Fig. 3. Maximum and minimum lifetime attributable risk (LAR) of imaging radiation induced cancer incidence. The stacked bar chart represents the estimated
lifetime attributable risk (LAR) of cancer due to protocol-requested chest-abdomen CT scans based on an estimated effective dose 16.5 mSv. A: The LAR of cancer for
the trial whose imaging protocol required the highest number of scans. B: The LAR of cancer for the trial (an adjuvant trial) whose imaging protocol required the
lowest number of scans. The data are presented separately for males (blue) and females (red).
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is the appropriate model to use in the setting of mandatory repeated CT
scans over a protracted period. Nevertheless, it should be emphasized
that the LNT model can be considered a conservative approach.
Therefore, the risk to develop cancer is probably lower. Secondly, for a
standardized U.S. population, the BEIR VII report predicts a cancer
baseline lifetime incidence of 44.9% for males and 37.5% for females
due to all causes [7]. Patients that have had a primary malignancy have
an increased risk for a secondary malignancy due to various reasons.
Therefore, the baseline lifetime incidence of cancer is probably higher
for these patients which could have influenced results. It could also be
argued that some patients that already developed cancer could be more
vulnerable to the mutagenic effects of diagnostic radiation due to di-
minished DNA repair mechanisms.
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